← All stocks

Entrada Therapeutics, Inc.

TRDA Net selling

CIK 0001689375 #3614 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$7.20M

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$7.20M

24 of 24 sales

Net

−$7.20M

−$7.20M against sales at will

By person

10 insiders · 24 transactions

5.8×

Dipal Doshi holds 5.8 times base salary in stock. $3.69M of shares against $635.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Dipal Doshi last reported holding, valued at $7.13, the price Common Stock was last bought or sold at on the open market here, on 9 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

MPM BioVentures 2014, L.P.

10% owner

—

$3.60M (12)

−$3.60M

8,203,463

21.07%

$58.49M

−6.2%

MPM BIOVENTURES 2018, L.P.

10% owner

—

$3.60M (12)

−$3.60M

8,203,463

21.07%

$58.49M

−6.2%

BAKER BROS. ADVISORS LP entity

10% owner

—

4,691,392

12.05%

$33.45M

+4.6%

5AM Ventures V, L.P. entity

10% owner

—

3,877,094

9.96%

$27.64M

−12.1%

PARMAR KUSH

Director

—

2,691,337

6.91%

$19.19M

−18.8%

Doshi Dipal

CEO

—

517,290

1.33%

$3.69M

+58.8%

Sethuraman Natarajan

President, Research & Develop.

—

214,238

0.5502%

$1.53M

+16.6%

Dowden Nathan J

President & COO

—

196,060

0.5035%

$1.40M

+55.6%

WENTWORTH KORY JAMES

Chief Financial Officer

—

117,277

0.3012%

$836.19K

+53.3%

Zeiher Bernhardt G

Director

—

5,000

0.0128%

$35.65K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 12

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 8

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 24

Transactions with no price 0

Shares from compensation/vesting 15,064

History held since 1 Nov 2021